CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its...
News
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),...
Vera Therapeutics to Host Business Update Call
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing...
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma...
VitalHub Announces SOC 2® Type 2 Compliance Underlining Ongoing Commitment to Security
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI), is pleased to announce that...
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership...
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by...
InMed Announces Management Changes
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled...
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing...
Jushi Holdings Inc. Completes Acquisition of Las Vegas, Nevada Dispensary and Establishes Fourth Vertically Integrated State-Level Operation
The Apothecarium1 in Las Vegas Marks Jushi’s First Dispensary in The State of Nevada Expands Permitted Licensed Retail Footprint to...
Axogen, Inc. publishes inaugural ESG Report
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that...
Tilray Medical Expands Offering in Malta and Launches First Medical Cannabis Oil Products in Market
LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a...
Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 – Conference Call to Follow
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a...
ProMIS Neurosciences Announces Fiscal Year 2021 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”...
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial,...
Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines...
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead...
